Predicted to enable GTPase activator activity and small GTPase binding activity. Predicted to be involved in negative regulation of cilium assembly. Predicted to be located in ciliary basal body; cytosol; and plasma membrane. Orthologous to human TBC1D30 (TBC1 domain family member 30); INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; amphetamine.
LOC102548194; LOC299824; RGD1305255; similar to CG3996-PA; TBC1 domain family member 30; TBC1 domain family member 30-like; uncharacterized protein LOC102548194
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA
[Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of TBC1D30 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of TBC1D30 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA